L-BASE
Latest round
- Series A
Last raised
- Jul 2018
Total raised
- $3.5M
Investors
- 4
About L-BASE
L-BASE, founded in 2015, is headquartered in Seoul, South Korea. The company focuses on developing therapeutic solutions for cancer, with a particular emphasis on innovative treatments. The founder, Do-yong Jeon, oversees the company's operations and strategic direction.L-BASE specializes in the development of innovative cancer therapies, primarily focusing on its flagship product, the CAGE-derived peptide-based treatment known as LB217. This therapeutic approach targets specific cancer antigens, known as Cancer-Testis Antigens (CTA), exclusively present in cancerous tissues. L-BASE's treatments inhibit autophagy in cancer cells while preserving it in healthy cells, addressing drug resistance commonly seen in existing cancer therapies. The company's primary focus is on non-small cell lung cancer (NSCLC), with ongoing clinical trials in Italy and plans for Phase 1 trials in the United Kingdom, slated for late 2025.L-BASE conducts its business primarily through partnerships with pharmaceutical companies and clinical research organizations to facilitate the development and potential commercialization of its proprietary therapies. The revenue model is based on strategic collaborations and licensing agreements, where partners fund clinical trials in exchange for product rights upon successful development. These transactions typically involve milestone payments tied to specific clinical and regulatory achievements and royalties on sales of any resulting therapies. Future growth strategies include the advancement of LB217 and the exploration of additional new cancer therapies. The company also aims to expand into new markets, focusing on Europe and North America, while continuing its clinical trials in Italy and initiating Phase 1 trials in the UK by late 2025.
Who invested in L-BASE
4 investors across 1 round
See all investors in L-BASE
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 20, 2018
Amount
$3.5M
Investors
Questions about L-BASE
Who invested in L-BASE?
L-BASE has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has L-BASE raised?
L-BASE has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did L-BASE last raise money?
L-BASE's most recent round on record is a Series A, in Jul 2018.
What does L-BASE do?
L-BASE, founded in 2015, is headquartered in Seoul, South Korea.
Where is L-BASE headquartered?
L-BASE is headquartered in Seoul, South Korea.
Which VCs invest in companies like L-BASE?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at L-BASE's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like L-BASE? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.